Allogene Therapeutics Inc. (NASDAQ:ALLO) Director Arie Belldegrun bought 35,000 shares of the company’s stock in a transaction dated Monday, October 15th. The shares were purchased at an average price of $18.00 per share, with a total value of $630,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Allogene Therapeutics stock opened at $23.40 on Friday. Allogene Therapeutics Inc. has a 1-year low of $21.67 and a 1-year high of $27.72.
Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.